Pliant Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
Current Price
$1.22
-1.61%Profile
Valuation (TTM)
Market Cap$74.97M
P/E-0.50
EV—
P/B0.41
Shares Out61.45M
P/Sales—
Revenue$0.00
EV/EBITDA—
Pliant Therapeutics Inc (PLRX) Stock Analysis
Market Cap$74.97M
Current Price$1.22
P/E Ratio-0.50
Forward P/E—
PEG Ratio0.01
EPS$-2.43
Book Value$2.95
P/B Ratio0.41
PLRX Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 18M
Revenue
57M
FY19
42M
FY20
8M
FY21
10M
FY22
2M
FY23
—
FY24
—
FY25
Net Income
—
FY19
—
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
PLRX 52-Week Range
$1.09
$1.87
50-Day MA: $1.28200-Day MA: $1.42
Did you know?
Price sits at 17% of its 52-week range.
Pliant Therapeutics Inc (PLRX) Financial Summary
Pliant Therapeutics Inc (PLRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $1.22 with a market capitalization of $74.97M.
Key valuation metrics include a P/E ratio of -0.50, price-to-book ratio of 0.41, and EPS of $-2.43. and return on equity of -82.4%.
PLRX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $74.97M |
| P/E Ratio | -0.50 |
| EPS | $-2.43 |
| P/B Ratio | 0.41 |
| Return on Equity | -82.4% |
| Debt/Equity | 0.16 |
PLRX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $57.05M | $-631000.00 |
| FY20 | $41.82M | $-41.53M |
| FY21 | $7.57M | $-97.26M |
| FY22 | $9.69M | $-123.32M |
| FY23 | $1.58M | $-161.34M |
| FY24 | $0.00 | $-210.30M |
| FY25 | $0.00 | $-149.34M |
About Pliant Therapeutics Inc
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
PLRX Free Cash Flow
Pliant Therapeutics Inc generated $-128.56M in trailing twelve-month free cash flow, representing an FCF yield of -171.48%. This low FCF yield may reflect heavy reinvestment or growth spending.
PLRX Shares Outstanding
Pliant Therapeutics Inc has 0.06 billion shares outstanding at a share price of $1.22, giving it a market capitalization of $74.97M.